New Zealand - English - Medsafe (Medicines Safety Authority)

actavis new zealand limited - metformin hydrochloride 1000mg;  ;   - coated tablet - 1000 mg - active: metformin hydrochloride 1000mg     excipient: magnesium stearate opadry clear oy-29020 povidone water - -treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. -metformin may be used as initial treatment or in sulfonylurea failures either alone or in combination with a sulfonylurea and other oral agents. - adjuvant therapy in insulin dependent diabetes especially if overweight.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - testosterone undecylate 1000mg;   - solution for injection - 1000 mg/4ml - active: testosterone undecylate 1000mg   excipient: benzyl benzoate castor oil - testosterone replacement in primary and secondary male hypogonadism

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - epoetin beta 1000 [iu] equivalent to 8.3 µg - powder for injection - 1000 iu - active: epoetin beta 1000 [iu] equivalent to 8.3 µg excipient: calcium chloride dihydrate dibasic sodium phosphate glutamic acid glycine isoleucine leucine monobasic sodium phosphate dihydrate nitrogen phenylalanine polysorbate 20 sodium chloride threonine urea water for injection

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

gulf drug llc saudi arabia - 1000ml non-pvc bag - infusion - 9g/1000ml - nutrition , blood-fluids , electrolytes

New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - octocog alfa 1000 [iu];   - injection with diluent - 1000 iu - active: octocog alfa 1000 [iu]   excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - advate is indicated for use in haemophilia a for prevention and control of haemorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von willebrand's disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - nonacog alfa 1000 [iu] (actually contains 1100 iu which includes 10% overage); nonacog alfa 1000 [iu] (actually contains 1100 iu which includes 10% overage) - powder for injection with diluent - 1000 iu - active: nonacog alfa 1000 [iu] (actually contains 1100 iu which includes 10% overage) excipient: glycine histidine polysorbate 80 sucrose water for injection active: nonacog alfa 1000 [iu] (actually contains 1100 iu which includes 10% overage) excipient: glycine histidine polysorbate 80 sucrose sodium chloride water for injection - for the control and prevention of haemorrhagic episodes in patients with haemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings.

New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - factor viii inhibitor bypassing fraction 1000 u;  ;   - powder for injection with diluent - 1000 u - active: factor viii inhibitor bypassing fraction 1000 u     excipient: sodium chloride sodium citrate dihydrate water for injection - feiba nf is indicated for treatment of haemorrhage and to cover surgical interventions in: · haemophilia a patients with factor viii inhibitors · haemophilia b patients with factor ix inhibitors. feiba nf is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in haemophilia a subjects with inhibitors experiencing >/= 12 bleeding episodes per year. prophylaxis with feiba nf is recommended for patients with high titer (>5bu) inhibitor or low titer (<5 bu) inhibitor, refractory to increased dosing with fviii or fix.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - amoxicillin sodium 1000mg;   - powder for injection - 1000 mg - active: amoxicillin sodium 1000mg   - amoxicillin should be used in accordance with local official antibiotic-prescribing guidelines and local susceptibility data. amoxicillin is indicated for the treatment of infections at the following sites, when caused by sensitive organism: · upper respiratory tract including ear, nose and throat infections, e.g. tonsillitis, sinusitis, otitis media. · lower respiratory tract, e.g. acute exacerbations of chronic bronchitis, lobar and bronchopneumonia. · gastrointestinal tract, e.g. typhoid fever. · genito-urinary tract, e.g. cystitis, urethritis, pyelonephritis, bacteriuria in pregnancy, gonorrhoea, septic abortion, puerperal sepsis. · other infections including borreliosis (borrelia burgdorferi) (lyme disease). · prophylaxis of endocarditis: amoxicillin may be used for the prevention of bacteraemia associated with the development of endocarditis. · skin and soft tissue infecitons (sstis). susceptibility to amoxicillin with vary with geography and time and local susceptibility data should be consulted where available and microbiological sampling and susceptibility testing performed where necessary.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - octocog alfa 1000 [iu] - injection with diluent - 1000 iu - active: octocog alfa 1000 [iu] excipient: calcium chloride dihydrate glycine histidine polysorbate 80 sodium chloride sucrose water for injection water for injection - kogenate fs is indicated in congenital factor viii deficiency (haemophilia a) for the treatment and prophylaxis of bleeding in untreated and previously treated patients without inhibitors.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - yellow fever vaccine 1000 [iu] (17d strain);   - suspension for injection - 1000 iu - active: yellow fever vaccine 1000 [iu] (17d strain)   excipient: alanine calcium chloride dihydrate dibasic sodium phosphate dihydrate histidine hydrochloride lactose monohydrate magnesium sulfate heptahydrate monobasic potassium phosphate potassium chloride sodium chloride sodium hydroxide sorbitol purified water sodium chloride - prevention of yellow fever. vaccination is recommended for: · every person over 9 months of age living or travelling through an endemic area. · non-vaccinated persons moving from an endemic to a potentially receptive non-endemic area. · laboratory workers handling potentially infectious materials. · in order to be officially recognised, the yellow fever vaccination must be administered in an approved vaccination centre and registered on an international certificate. the validity period of the certificate is established according to international health regulations recommendations and starts 10 days after primary vaccination and immediately after re-vaccination.